maklogo
Market Research Report

Global Sickle Cell Anemia Testing and Screening Market Insights, Size, and Forecast By Application (Diagnosis, Carrier Testing, Prenatal Testing), By Technique (Blood Test, Saliva Test, Molecular Testing), By Test Type (Hemoglobin Electrophoresis, Newborn Screening Tests, Genetic Testing, Sickle Cell Screening), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Research Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:25924
Published Date:Jan 2026
No. of Pages:233
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Sickle Cell Anemia Testing and Screening Market is projected to grow from USD 3.8 Billion in 2025 to USD 8.1 Billion by 2035, reflecting a compound annual growth rate of 8.6% from 2026 through 2035. This market encompasses a wide array of diagnostic tools and procedures designed to identify the presence of sickle cell disease or the sickle cell trait in individuals. The increasing global prevalence of sickle cell anemia, particularly in regions with high genetic predispositions, is a primary market driver. Enhanced awareness programs, government initiatives aimed at early diagnosis, and technological advancements in diagnostic methodologies further propel market expansion. The market is segmented by Test Type, Technique, End User, and Application, with the Hospitals segment currently holding the largest share, underscoring their crucial role in diagnosis and patient management. Early and accurate diagnosis of sickle cell anemia is paramount for effective disease management, preventing complications, and improving patient quality of life. The rise in newborn screening programs worldwide is a significant trend, contributing to earlier intervention and better long-term outcomes. However, challenges such as the high cost of advanced diagnostic tests in resource-limited settings and a lack of standardized testing protocols in certain regions act as restraints. Despite these hurdles, the market presents substantial opportunities with the development of more affordable and point-of-care testing solutions, expanding reach into underserved populations.

Global Sickle Cell Anemia Testing and Screening Market Value (USD Billion) Analysis, 2025-2035

maklogo
8.6%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

North America stands as the dominant region in the global sickle cell anemia testing and screening market, driven by robust healthcare infrastructure, high awareness levels, favorable reimbursement policies, and the strong presence of key market players. The region benefits from significant investments in research and development for genetic testing and early disease detection. Conversely, the Middle East and Africa is poised to be the fastest-growing region. This accelerated growth is attributed to a high incidence of sickle cell disease, increasing government focus on public health initiatives, improving healthcare accessibility, and growing awareness campaigns targeting at-risk populations. The expansion of newborn screening programs and the adoption of advanced diagnostic technologies in these emerging markets are key factors underpinning this rapid expansion. The imperative for early detection and intervention in regions heavily impacted by sickle cell disease is a strong catalyst for market growth.

Key players such as Thermo Fisher Scientific, Beckman Coulter, Abbott Laboratories, Roche Diagnostics, Grifols, Quest Diagnostics, BioRad Laboratories, Genetic Technologies, Hemoglobinopathy Testing, and Siemens Healthineers are actively shaping the competitive landscape. These companies are employing diverse strategies, including product innovation, strategic collaborations, mergers and acquisitions, and geographical expansion, to strengthen their market positions. Their focus lies on developing more accurate, rapid, and cost-effective diagnostic solutions, including molecular diagnostics and next-generation sequencing techniques. Partnerships with public health organizations and government bodies are also crucial for expanding screening programs and improving access to testing, especially in regions with high disease burden. The ongoing research into non-invasive diagnostic methods and high-throughput screening technologies represents a significant area of future growth and competitive differentiation.

Quick Stats

  • Market Size (2025):

    USD 3.8 Billion

  • Projected Market Size (2035):

    USD 8.1 Billion

  • Leading Segment:

    Hospitals (45.8% Share)

  • Dominant Region (2025):

    North America (38.2% Share)

  • CAGR (2026-2035):

    8.6%

What is Sickle Cell Anemia Testing and Screening?

Sickle cell anemia testing and screening identifies individuals carrying the sickle cell trait or having sickle cell disease. Newborn screening is crucial, using blood samples to detect abnormal hemoglobin, allowing for early diagnosis and intervention. Prenatal testing can be performed on amniotic fluid or chorionic villus samples to determine if a fetus is affected. Carrier screening identifies individuals who carry one copy of the gene, providing important information for family planning and genetic counseling. This testing is vital for preventing serious health complications, guiding treatment strategies, and making informed reproductive decisions, especially in populations with a higher prevalence of the disease.

What are the Trends in Global Sickle Cell Anemia Testing and Screening Market

  • Genomic Screening Ascendancy

  • Point of Care Innovations Proliferate

  • Newborn Screening Expansion

  • Telehealth Integration for Access

Genomic Screening Ascendancy

Genomic screening is gaining prominence in global sickle cell anemia testing due to its precision and breadth. It enables early, accurate diagnosis including carrier status and disease severity prediction. Advanced sequencing technologies are replacing traditional methods, offering comprehensive genetic insights beyond single gene defects. This shift improves diagnostic accuracy, informs personalized treatment strategies, and enhances family planning options, driving its widespread adoption in screening programs globally.

Point of Care Innovations Proliferate

Point of care innovations proliferate as accessible, rapid sickle cell anemia testing becomes critical. These devices decentralize screening, moving it closer to patients especially in resource constrained settings. They offer immediate results, facilitating earlier diagnosis and intervention. This trend minimizes delays associated with traditional lab based methods, enhancing screening program effectiveness and patient management globally.

Newborn Screening Expansion

Newborn screening for sickle cell anemia is broadening globally. Countries are increasingly implementing or expanding programs to test all newborns for the condition at birth. This allows for early diagnosis and intervention, significantly improving health outcomes and reducing mortality for affected infants. The trend reflects growing awareness of sickle cell disease and the long term benefits of early detection and management.

Telehealth Integration for Access

Telehealth integration expands access to sickle cell anemia testing and screening, especially in remote or underserved areas. Virtual consultations and remote sample collection reduce geographical barriers, facilitating earlier diagnosis and management. This trend enhances outreach, ensuring more individuals receive timely screenings and genetic counseling regardless of location, improving overall public health outcomes for sickle cell patients globally.

What are the Key Drivers Shaping the Global Sickle Cell Anemia Testing and Screening Market

  • Rising Global Prevalence of Sickle Cell Anemia

  • Advancements in Newborn Screening Technologies

  • Increasing Awareness and Government Initiatives

  • Growing Investment in Research and Development

Rising Global Prevalence of Sickle Cell Anemia

The increasing number of individuals diagnosed with sickle cell anemia worldwide is a significant driver. This growing patient population necessitates more extensive testing and screening efforts to identify affected individuals, particularly newborns and carriers. Enhanced awareness and improved diagnostic capabilities also contribute to the rising reported prevalence, further stimulating demand for screening solutions globally.

Advancements in Newborn Screening Technologies

Newborn screening advancements are transforming early sickle cell anemia detection. Innovations in laboratory techniques and point of care diagnostics enable faster, more accurate identification of affected infants. This allows timely interventions, improving patient outcomes and reducing disease severity. Expanded screening programs, driven by these technologies, are crucial for broader population coverage and more effective disease management globally.

Increasing Awareness and Government Initiatives

Global efforts emphasizing early diagnosis and management of sickle cell anemia are expanding. Governments and health organizations are launching campaigns to educate the public about the condition’s prevalence and the importance of screening. These initiatives boost demand for testing services by promoting informed decision-making and access to healthcare.

Growing Investment in Research and Development

Increased funding fuels discovery of novel sickle cell anemia tests and screening methods. This investment supports advanced research into genetic markers, innovative diagnostic technologies, and improved screening protocols for newborns and at-risk populations. Consequently, the market expands with better and more accessible testing solutions.

Global Sickle Cell Anemia Testing and Screening Market Restraints

Lack of Universal Newborn Screening Programs

Inconsistent or absent newborn screening for sickle cell anemia across various countries limits early detection and intervention. Without universal programs, many affected infants are not identified at birth, delaying access to life saving treatments and preventative care. This significantly hinders market growth for screening tests and related services, particularly in regions where healthcare infrastructure is underdeveloped or not prioritized for comprehensive newborn health initiatives.

High Cost of Advanced Diagnostic Technologies

The high cost of advanced diagnostic technologies poses a significant barrier. Specialized equipment and skilled personnel required for accurate sickle cell anemia testing, particularly in resource limited settings, inflate expenses. This financial burden restricts widespread adoption of sophisticated screening methods, limiting access to early diagnosis. Consequently, populations in regions with strained healthcare budgets struggle to implement comprehensive testing programs, hindering effective disease management and prevention efforts globally.

Global Sickle Cell Anemia Testing and Screening Market Opportunities

Global Expansion of Universal Newborn and Carrier Sickle Cell Screening Programs

The global expansion of universal newborn and carrier sickle cell screening programs offers a transformative opportunity. Many regions, particularly those with high disease prevalence, currently lack comprehensive screening infrastructure. Implementing widespread newborn screening ensures early diagnosis and interventions, significantly improving patient outcomes and quality of life. Expanding carrier screening empowers individuals and couples with crucial genetic information for informed family planning decisions, thereby preventing new cases. This growing emphasis on proactive health management and prevention across underserved populations globally will drive substantial demand for advanced testing technologies, diagnostic kits, and related healthcare services.

Point-of-Care and Decentralized Diagnostics for Enhanced Global Accessibility

Point of care and decentralized diagnostics present a significant opportunity to expand global sickle cell anemia testing access. These methods enable rapid, convenient screening outside central laboratories, reaching underserved populations in remote and resource limited settings effectively. This enhances accessibility for early diagnosis, particularly for newborns in high prevalence regions like Africa and the Middle East. Such widespread testing facilitates timely intervention, improves patient outcomes, and transforms global sickle cell management and prevention efforts.

Global Sickle Cell Anemia Testing and Screening Market Segmentation Analysis

Key Market Segments

By Test Type

  • •Hemoglobin Electrophoresis
  • •Newborn Screening Tests
  • •Genetic Testing
  • •Sickle Cell Screening

By Technique

  • •Blood Test
  • •Saliva Test
  • •Molecular Testing

By End User

  • •Hospitals
  • •Diagnostic Laboratories
  • •Blood Banks
  • •Research Institutes

By Application

  • •Diagnosis
  • •Carrier Testing
  • •Prenatal Testing

Segment Share By Test Type

Share, By Test Type, 2025 (%)

  • Hemoglobin Electrophoresis
  • Newborn Screening Tests
  • Sickle Cell Screening
  • Genetic Testing
maklogo
$3.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why are Hospitals dominating the Global Sickle Cell Anemia Testing and Screening Market?

Hospitals serve as primary points of care for individuals with sickle cell anemia, from initial diagnosis to ongoing management. Their comprehensive infrastructure supports a wide array of testing services, including advanced genetic testing and newborn screening. Patients often seek hospital facilities for reliable and integrated healthcare, ensuring access to specialized equipment, skilled medical professionals, and immediate follow up care, contributing significantly to their leading market share.

What makes Hemoglobin Electrophoresis a cornerstone in Sickle Cell Anemia testing?

Hemoglobin Electrophoresis remains a fundamental and widely utilized test due to its accuracy in identifying different types of hemoglobin, including abnormal hemoglobin S indicative of sickle cell disease or trait. It is an indispensable tool for initial diagnosis and confirmatory testing, particularly valuable in regions with high prevalence. Its established reliability and relatively accessible nature make it a preferred method across various healthcare settings.

How does the application of Diagnosis drive the Sickle Cell Anemia Testing Market?

Diagnosis forms the foundational application driving the entire sickle cell anemia testing market. Early and accurate diagnosis is critical for initiating appropriate treatment, preventing severe complications, and improving patient quality of life. All other applications, such as carrier testing and prenatal testing, ultimately stem from the need to diagnose or identify risk factors for the condition, making it the most expansive and impactful segment in terms of market activity.

What Regulatory and Policy Factors Shape the Global Sickle Cell Anemia Testing and Screening Market

The global sickle cell anemia testing market navigates a complex regulatory mosaic. Agencies like the FDA, EMA, and national health ministries govern diagnostic test approvals, ensuring safety and efficacy. Ethical guidelines concerning genetic screening, patient data privacy, and informed consent are increasingly stringent globally. Newborn screening mandates in many developed and some developing nations drive consistent market demand. Reimbursement policies from public and private insurers significantly impact market access and adoption, varying widely by region. The World Health Organization offers guidelines often adopted by low and middle income countries, influencing policy development. Quality assurance, laboratory accreditation, and test standardization remain critical across all jurisdictions. Harmonization efforts exist but regional differences persist.

What New Technologies are Shaping Global Sickle Cell Anemia Testing and Screening Market?

Innovations are rapidly advancing sickle cell anemia testing and screening. Point of care devices enable rapid, accessible diagnosis, especially in resource limited settings, driving early intervention. Next generation sequencing offers enhanced accuracy for carrier screening and newborn diagnostics, refining genetic risk assessment. Microfluidic technologies contribute to miniaturization and cost effective testing platforms. Non invasive prenatal testing provides crucial early detection options. Artificial intelligence and machine learning improve diagnostic precision and data interpretation, streamlining workflows. These emerging technologies collectively expand screening capabilities, accelerate time to result, and enhance diagnostic accuracy globally, significantly contributing to market growth by improving early detection and management strategies.

Global Sickle Cell Anemia Testing and Screening Market Regional Analysis

Global Sickle Cell Anemia Testing and Screening Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

North America dominates the global sickle cell anemia testing and screening market with a substantial 38.2% share. This leadership position is driven by several factors, including advanced healthcare infrastructure, high awareness regarding genetic disorders, and significant investment in research and development. The presence of key market players and a robust regulatory framework also contribute to the region's strong market performance. Early detection and comprehensive screening programs for newborns and high-risk populations are well-established, further fueling the demand for testing solutions. The region benefits from accessibility to innovative diagnostic technologies and consistent efforts to improve patient outcomes through effective screening.

Europe's sickle cell anemia testing and screening market is driven by rising immigration from endemic regions and advanced healthcare infrastructure. Western Europe, particularly the UK, France, and Germany, leads in market share due to established screening programs and higher awareness. Eastern European countries are experiencing growth as healthcare systems improve and the prevalence of the disease increases with changing demographics. Public health initiatives, coupled with advancements in non-invasive prenatal testing and newborn screening, further contribute to market expansion across the continent. Future growth is anticipated with increased funding for rare disease diagnostics.

The Asia Pacific sickle cell anemia testing and screening market is nascent but growing, driven by increasing awareness and improving healthcare infrastructure. While prevalence is historically lower than in other regions, rising migratory patterns and increased genetic screening are contributing to market expansion. India, with its diverse genetic pool, presents a significant potential market. However, challenges like limited access to advanced diagnostics in rural areas and the need for greater public health initiatives remain. Japan and Australia, with established healthcare systems, focus on advanced prenatal and newborn screening technologies, albeit for a smaller patient base.

Latin America faces unique challenges in sickle cell anemia testing and screening due to diverse healthcare infrastructure and access. While some countries have established newborn screening programs, many lack comprehensive coverage, particularly in rural and indigenous communities. Resource limitations, varying healthcare priorities, and limited awareness among healthcare providers and the public contribute to late diagnosis and inadequate management. Implementing cost-effective, decentralized screening strategies and strengthening public health initiatives are crucial for improving early detection and patient outcomes across the region. Regional collaborations can foster knowledge sharing and resource optimization to address these disparities effectively.

The Middle East & Africa sickle cell anemia testing and screening market exhibits significant regional variation. Sub-Saharan Africa, particularly Nigeria and Democratic Republic of Congo, drives demand due to high prevalence rates, prompting increased newborn screening and carrier testing initiatives. Government and non-profit organizations play a crucial role in expanding access to affordable diagnostics. In the Middle East, while prevalence is lower, genetic testing and premarital screening programs are well-established in countries like Saudi Arabia and UAE. Market growth is further fueled by rising awareness, improving healthcare infrastructure, and the introduction of point-of-care testing solutions across the entire region, targeting early diagnosis and disease management.

Top Countries Overview

The United States is a significant contributor to global sickle cell anemia testing and screening, driven by newborn screening programs and increasing prenatal testing. Technological advancements and growing awareness about the disease's prevalence in diverse populations further fuel market expansion and innovation in diagnostic tools.

China's role in global sickle cell anemia testing and screening is growing. Increased awareness, government initiatives, and improved healthcare infrastructure drive domestic market expansion. Chinese companies contribute to diagnostics and research, impacting global screening capabilities and patient management strategies for the disease.

India is a significant market for sickle cell anemia testing due to high disease prevalence. Government initiatives and increased awareness are driving demand for screening and diagnostic solutions. This growing market offers immense opportunities for global players.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability influences funding for rare disease research and public health initiatives in endemic regions. Conflict disrupts healthcare infrastructure, hindering access to testing and screening, particularly in sub-Saharan Africa. International collaborations and aid packages for sickle cell anemia programs are sensitive to shifting geopolitical alliances and priorities among donor nations.

Macroeconomic conditions directly impact healthcare budgets and patient affordability. Economic downturns reduce government spending on newborn screening programs and may limit the availability of advanced diagnostic tests. Conversely, economic growth in developing countries could foster increased investment in healthcare infrastructure and improved access to affordable screening technologies, expanding market penetration for testing solutions.

Recent Developments

  • March 2025

    Thermo Fisher Scientific launched an advanced high-throughput screening platform specifically designed for newborn sickle cell anemia detection. This new system offers faster results and improved accuracy, significantly reducing the turnaround time for critical early diagnosis.

  • July 2024

    Abbott Laboratories announced a strategic partnership with Genetic Technologies to integrate their next-generation sequencing (NGS) capabilities into existing sickle cell carrier screening panels. This collaboration aims to provide a more comprehensive and precise assessment of genetic risk factors for carriers.

  • September 2024

    Quest Diagnostics completed the acquisition of a specialized point-of-care testing company focusing on rapid sickle cell anemia diagnostics. This acquisition expands Quest's footprint in decentralized testing solutions, making screening more accessible in remote and underserved communities.

  • February 2025

    Siemens Healthineers introduced an AI-powered diagnostic algorithm for automated analysis of blood smear images in sickle cell disease diagnosis. This innovative tool promises to enhance diagnostic efficiency and reduce inter-observer variability in microscopic examinations.

  • April 2025

    Roche Diagnostics initiated a global strategic initiative to increase access to affordable sickle cell screening in low-income countries, partnering with local governments and NGOs. This program includes the deployment of their robust diagnostic instruments and training for healthcare professionals.

Key Players Analysis

Key players in the Global Sickle Cell Anemia Testing and Screening Market like Thermo Fisher Scientific, Beckman Coulter, Abbott Laboratories, and Roche Diagnostics are pivotal in driving market expansion. These giants specialize in developing sophisticated diagnostic platforms utilizing technologies such as high performance liquid chromatography (HPLC), capillary electrophoresis, and molecular diagnostics. Their strategic initiatives include robust research and development, partnerships, and global distribution networks. Quest Diagnostics and Grifols play crucial roles in specialized testing services and advanced therapeutics, respectively, further fueling market growth through comprehensive solutions and improved patient outcomes. Siemens Healthineers also contributes significantly with its integrated diagnostic offerings.

List of Key Companies:

  1. Thermo Fisher Scientific
  2. Beckman Coulter
  3. Abbott Laboratories
  4. Roche Diagnostics
  5. Grifols
  6. Quest Diagnostics
  7. BioRad Laboratories
  8. Genetic Technologies
  9. Hemoglobinopathy Testing
  10. Siemens Healthineers
  11. Cepheid
  12. Biorad
  13. Sankyo Seiko
  14. Arup Laboratories
  15. NantHealth
  16. New England Biolabs

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 3.8 Billion
Forecast Value (2035)USD 8.1 Billion
CAGR (2026-2035)8.6%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Test Type:
    • •Hemoglobin Electrophoresis
    • •Newborn Screening Tests
    • •Genetic Testing
    • •Sickle Cell Screening
  • By Technique:
    • •Blood Test
    • •Saliva Test
    • •Molecular Testing
  • By End User:
    • •Hospitals
    • •Diagnostic Laboratories
    • •Blood Banks
    • •Research Institutes
  • By Application:
    • •Diagnosis
    • •Carrier Testing
    • •Prenatal Testing
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
5.1.1. Hemoglobin Electrophoresis
5.1.2. Newborn Screening Tests
5.1.3. Genetic Testing
5.1.4. Sickle Cell Screening
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
5.2.1. Blood Test
5.2.2. Saliva Test
5.2.3. Molecular Testing
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
5.3.1. Hospitals
5.3.2. Diagnostic Laboratories
5.3.3. Blood Banks
5.3.4. Research Institutes
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.4.1. Diagnosis
5.4.2. Carrier Testing
5.4.3. Prenatal Testing
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
6.1.1. Hemoglobin Electrophoresis
6.1.2. Newborn Screening Tests
6.1.3. Genetic Testing
6.1.4. Sickle Cell Screening
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
6.2.1. Blood Test
6.2.2. Saliva Test
6.2.3. Molecular Testing
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
6.3.1. Hospitals
6.3.2. Diagnostic Laboratories
6.3.3. Blood Banks
6.3.4. Research Institutes
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.4.1. Diagnosis
6.4.2. Carrier Testing
6.4.3. Prenatal Testing
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
7.1.1. Hemoglobin Electrophoresis
7.1.2. Newborn Screening Tests
7.1.3. Genetic Testing
7.1.4. Sickle Cell Screening
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
7.2.1. Blood Test
7.2.2. Saliva Test
7.2.3. Molecular Testing
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Blood Banks
7.3.4. Research Institutes
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.4.1. Diagnosis
7.4.2. Carrier Testing
7.4.3. Prenatal Testing
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
8.1.1. Hemoglobin Electrophoresis
8.1.2. Newborn Screening Tests
8.1.3. Genetic Testing
8.1.4. Sickle Cell Screening
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
8.2.1. Blood Test
8.2.2. Saliva Test
8.2.3. Molecular Testing
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Blood Banks
8.3.4. Research Institutes
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.4.1. Diagnosis
8.4.2. Carrier Testing
8.4.3. Prenatal Testing
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
9.1.1. Hemoglobin Electrophoresis
9.1.2. Newborn Screening Tests
9.1.3. Genetic Testing
9.1.4. Sickle Cell Screening
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
9.2.1. Blood Test
9.2.2. Saliva Test
9.2.3. Molecular Testing
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Blood Banks
9.3.4. Research Institutes
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.4.1. Diagnosis
9.4.2. Carrier Testing
9.4.3. Prenatal Testing
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
10.1.1. Hemoglobin Electrophoresis
10.1.2. Newborn Screening Tests
10.1.3. Genetic Testing
10.1.4. Sickle Cell Screening
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Technique
10.2.1. Blood Test
10.2.2. Saliva Test
10.2.3. Molecular Testing
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End User
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Blood Banks
10.3.4. Research Institutes
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.4.1. Diagnosis
10.4.2. Carrier Testing
10.4.3. Prenatal Testing
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Thermo Fisher Scientific
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Beckman Coulter
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Abbott Laboratories
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Roche Diagnostics
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Grifols
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Quest Diagnostics
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. BioRad Laboratories
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Genetic Technologies
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Hemoglobinopathy Testing
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Siemens Healthineers
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Cepheid
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Biorad
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Sankyo Seiko
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Arup Laboratories
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. NantHealth
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. New England Biolabs
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 2: Global Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 3: Global Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 4: Global Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 5: Global Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 7: North America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 8: North America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 9: North America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 10: North America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 12: Europe Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 13: Europe Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 14: Europe Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 15: Europe Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 17: Asia Pacific Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 18: Asia Pacific Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 19: Asia Pacific Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 20: Asia Pacific Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 22: Latin America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 23: Latin America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 24: Latin America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 25: Latin America Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 27: Middle East & Africa Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Technique, 2020-2035

Table 28: Middle East & Africa Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 29: Middle East & Africa Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 30: Middle East & Africa Sickle Cell Anemia Testing and Screening Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Aerospace Defense Market Research

Explore comprehensive market research reports covering all aspects of the Aerospace Defense industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;